Dextenza demonstrated a statistically significant mean change in ocular itching scores from baseline in patients with allergic conjunctivitis, according to a press release from Ocular Therapeutix.
Ninety-six participants were enrolled in a phase 3 randomized, double-masked, parallel-arm, placebo-controlled clinical trial at six sites in the United States. The primary endpoint was ocular itching measured on a 5-point scale at three prespecified time points on day 8 after implantation. The trial included patients with seasonal and perennial allergies.
Mean itch scores, on a scale of 0 to 4, at 3